BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kong WJ, Vernieri C, Foiani M, Jiang JD. Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. Pharmacol Ther 2020;209:107496. [PMID: 32001311 DOI: 10.1016/j.pharmthera.2020.107496] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Li YH, Zou M, Han Q, Deng LR, Weinshilboum RM. Therapeutic potential of triterpenoid saponin anemoside B4 from Pulsatilla chinensis. Pharmacol Res 2020;160:105079. [PMID: 32679180 DOI: 10.1016/j.phrs.2020.105079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Chen H, Zhang F, Zhang J, Zhang X, Guo Y, Yao Q. A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis. Front Immunol 2020;11:588079. [PMID: 33072135 DOI: 10.3389/fimmu.2020.588079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Ni WJ, Guan XM, Zeng J, Zhou H, Meng XM, Tang LQ. Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway. J Cell Mol Med 2022. [PMID: 35001506 DOI: 10.1111/jcmm.17167] [Reference Citation Analysis]
4 Yang S, Li D, Yu Z, Li Y, Wu M. Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota. Front Pharmacol 2021;12:709629. [PMID: 34305616 DOI: 10.3389/fphar.2021.709629] [Reference Citation Analysis]
5 Chou WL. Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia. Pharmacol Res 2021;170:105693. [PMID: 34048925 DOI: 10.1016/j.phrs.2021.105693] [Reference Citation Analysis]
6 Di Bisceglie AM, Watts GF, Lavin P, Yu M, Bai R, Liu L. Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids Health Dis 2020;19:239. [PMID: 33183320 DOI: 10.1186/s12944-020-01406-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Li D, Yang C, Zhu JZ, Lopez E, Zhang T, Tong Q, Peng C, Lin LG. Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3. Acta Pharmacol Sin 2021. [PMID: 34417576 DOI: 10.1038/s41401-021-00736-y] [Reference Citation Analysis]
8 Cheng Y, Ji Y, Tong J. Triple stimuli-responsive supramolecular nanoassembly with mitochondrial targetability for chemophotothermal therapy. Journal of Controlled Release 2020;327:35-49. [DOI: 10.1016/j.jconrel.2020.08.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Ottanà R, Paoli P, Cappiello M, Nguyen TN, Adornato I, Del Corso A, Genovese M, Nesi I, Moschini R, Naß A, Wolber G, Maccari R. In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications-A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B. Molecules 2021;26:E330. [PMID: 33435264 DOI: 10.3390/molecules26020330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Xia Y, Chen S, Cui J, Wang Y, Liu X, Shen Y, Gong L, Jiang X, Wang W, Zhu Y, Sun S, Li J, Zou Y, Shi B. Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p. Biochem Pharmacol 2021;188:114575. [PMID: 33887260 DOI: 10.1016/j.bcp.2021.114575] [Reference Citation Analysis]
11 Wang D, Zhang P, Mei X, Chen Z. Repair calvarial defect of osteoporotic rats by berberine functionalized porous calcium phosphate scaffold. Regen Biomater 2021;8:rbab022. [PMID: 34211732 DOI: 10.1093/rb/rbab022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhang W, Xu C, Sun J, Shen H, Wang J, Yang C. Impairment of the autophagy–lysosomal pathway in Alzheimer’s diseases: Pathogenic mechanisms and therapeutic potential. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.01.008] [Reference Citation Analysis]
13 Zhang XH, Peng L, Zhang J, Dong YP, Wang CJ, Liu C, Xia DY, Zhang XS. Berberine Ameliorates Subarachnoid Hemorrhage Injury via Induction of Sirtuin 1 and Inhibiting HMGB1/Nf-κB Pathway. Front Pharmacol 2020;11:1073. [PMID: 32754040 DOI: 10.3389/fphar.2020.01073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Fan YT, Zhong P, Xu JD, Zhou SS, Kong M, Zhou GR, Mao Q, Li SL. Integrating multiple-chromatographic approaches to evaluate chemical consistency of Chang-Kang-Fang preparations from mixed-herb decoction and combined single-herb decoction. J Pharm Biomed Anal 2021;203:114186. [PMID: 34118572 DOI: 10.1016/j.jpba.2021.114186] [Reference Citation Analysis]
15 Tang R, Li R, Li H, Ma XL, Du P, Yu XY, Ren L, Wang LL, Zheng WS. Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease. ACS Nano 2021. [PMID: 34705426 DOI: 10.1021/acsnano.1c02158] [Reference Citation Analysis]
16 Zhou YX, Gong XH, Zhang H, Peng C. A review on the pharmacokinetics of paeoniflorin and its anti-inflammatory and immunomodulatory effects. Biomed Pharmacother 2020;130:110505. [PMID: 32682112 DOI: 10.1016/j.biopha.2020.110505] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
17 Quan Y, Li L, Yin Z, Chen S, Yi J, Lang J, Zhang L, Yue Q, Zhao J. Bulbus Fritillariae Cirrhosae as a Respiratory Medicine: Is There a Potential Drug in the Treatment of COVID-19? Front Pharmacol 2022;12:784335. [DOI: 10.3389/fphar.2021.784335] [Reference Citation Analysis]
18 Han Q, Tang HZ, Zou M, Zhao J, Wang L, Bian ZX, Li YH. Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models. J Nat Prod 2020;83:1939-49. [PMID: 32432470 DOI: 10.1021/acs.jnatprod.0c00175] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wang C, Cheng Y, Zhang Y, Jin H, Zuo Z, Wang A, Huang J, Jiang J, Kong W. Berberine and Its Main Metabolite Berberrubine Inhibit Platelet Activation Through Suppressing the Class I PI3Kβ/Rasa3/Rap1 Pathway. Front Pharmacol 2021;12:734603. [PMID: 34690771 DOI: 10.3389/fphar.2021.734603] [Reference Citation Analysis]
20 Ming J, Yu X, Xu X, Wang L, Ding C, Wang Z, Xie X, Li S, Yang W, Luo S, He Q, Du Y, Tian Z, Gao X, Ma K, Fang Y, Li C, Zhao J, Wang X, Ji Q. Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. Genome Med 2021;13:125. [PMID: 34365978 DOI: 10.1186/s13073-021-00942-7] [Reference Citation Analysis]
21 Galano A, Guzmán-López EG, Reiter RJ. Potentiating the Benefits of Melatonin through Chemical Functionalization: Possible Impact on Multifactorial Neurodegenerative Disorders. Int J Mol Sci 2021;22:11584. [PMID: 34769013 DOI: 10.3390/ijms222111584] [Reference Citation Analysis]